Akorn, Inc. (NASDAQ:AKRX)
CAPS Rating:
The Company manufactures and markets diagnostic and therapeutic pharmaceuticals in specialty areas such as ophthalmology, rheumatology, anesthesia and antidotes, among others.
The Company manufactures and markets diagnostic and therapeutic pharmaceuticals in specialty areas such as ophthalmology, rheumatology, anesthesia and antidotes, among others.
Recs
I don't think the analysts are aware of the scope of the generic market. Some are saying (Deutsche) that Akorn will not manufacture enough generics? How do they know when the FDA is not working with DEA to know what's in the pipeline or which drugs will be approved?